Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylphenidate
Drug ID BADD_D01431
Description Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally inappropriate symptoms associated with ADHD: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Long-acting formulations of psychostimulants such as methylphenidate, [DB01576], and [DB01255] are considered the most effective and widely used treatment for ADHD, and are considered first-line options for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective.
Indications and Usage Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.
Marketing Status approved; investigational
ATC Code N06BA04
DrugBank ID DB00422
KEGG ID D04999
MeSH ID D008774
PubChem ID 4158
TTD Drug ID D02PPN
NDC Product Code 0781-2363; 0378-8263; 0574-2420; 0406-7654; 70165-200; 0378-8261; 68968-5552; 68968-5555; 70165-100; 0781-2362; 0781-2364; 0378-8262; 0574-2410; 0574-2430; 0574-2415; 68968-5553; 70165-300; 68968-5554; 0781-2361; 0378-8260
UNII 207ZZ9QZ49
Synonyms Methylphenidate | Metadate | Equasym | Methylin | Concerta | Phenidylate | Ritalin | Ritaline | Ritalin-SR | Ritalin SR | Tsentedrin | Centedrin | Daytrana | Methylphenidate Hydrochloride | Hydrochloride, Methylphenidate
Chemical Information
Molecular Formula C14H19NO2
CAS Registry Number 113-45-1
SMILES COC(=O)C(C1CCCCN1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Depression19.15.01.0010.002134%
Derealisation19.10.05.004---
Dermatitis23.03.04.002---
Dermatitis allergic10.01.03.014; 23.03.04.0030.000140%-
Dermatitis atopic10.01.04.004; 23.03.04.0160.000090%-
Dermatitis bullous23.03.01.002--
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.0040.000280%-
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.000041%
Diabetes mellitus05.06.01.001; 14.06.01.001---
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.0050.000132%-
Discomfort08.01.08.0030.000362%-
Disinhibition19.05.01.0020.000041%-
Disorientation17.02.05.015; 19.13.01.0020.000123%-
Dissociation19.14.01.0020.000090%-
Distractibility19.21.02.0070.000160%-
Disturbance in attention17.03.03.001; 19.21.02.0020.004683%
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dizziness postural02.11.04.008; 17.02.05.004; 24.06.02.0080.000041%-
Drooling17.02.05.005---
Drug abuse19.07.06.0100.002200%-
Drug dependence19.07.06.011---
Drug eruption08.01.06.015; 10.01.01.005; 23.03.05.001---
Drug ineffective08.06.01.0060.027353%-
Drug interaction08.06.03.001---
Dry eye06.08.02.001--
Dry mouth07.06.01.0020.000284%
Dry skin23.03.03.001--
Dysaesthesia17.02.06.003; 23.03.03.0770.000041%
Dysarthria17.02.08.001; 19.19.03.0010.000275%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene